Medindia

X

FDA Advisory Panel to Re-Evaluate Popular Osteoporosis Drugs

by Kathy Jones on  September 8, 2011 at 5:35 PM Drug News   - G J E 4
Popular osteoporosis drugs known as bisphosphonates are being re-evaluated by the advisory panel of the US Food and Drug Administration after recent studies linked this class of drugs with brittle bones in thighs and the jaw.
 FDA Advisory Panel to Re-Evaluate Popular Osteoporosis Drugs
FDA Advisory Panel to Re-Evaluate Popular Osteoporosis Drugs
Advertisement

A study conducted by the American Society of Bone and Mineral Research last September revealed that bisphosphonates increased the risk of rare femur fracture among patients suffering from osteoporosis. The researchers observed 310 cases of such fractures and found that more than 94 percent of them had taken the drugs.

Advertisement
The researchers suggested that the FDA should consider their study and change the drugs' labeling to display warnings of such risks.

One of the popular bisphosphonate drugs, Fosamax, has also been linked with osteonecrosis of the jaw, though its manufacturer Merck said that the studies lack any clinical evidence.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All